C-Reactive Protein Testing Market

The C-Reactive Protein Testing Market is valued at USD 5.5 Bn in 2026 and is projected to reach USD 6.2 Bn, growing at a CAGR of 2% by 2033.Rising incidences of chronic ailments such as cancer, cardiovascular disorders, inflammatory bowel diseases, and arthritis continue to favor the adoption of CRP testing, in turn complementing the growth of the c-reactive protein testing market. For instance, according to CDC, by end of 2040, around 78 million adults in the United States aged 18 years and above are expected to develop diagnosed arthritis. Early identification and diagnosis of chronic diseases can improve patient outcomes and increase the probability of a successful treatment. This aspect continues to spur the adoption of CRP tests, consequently favording the growth of the c-reactive protein testing market.

COVID-19 Infection Severity to Present Lucrative Opportunities of Growth for C-Reactive Protein Testing Market

COVID 19 pandemic has significantly fuelled the growth of the c-reactive protein testing market since 2020. According to National Center for Biotechnology Information, in 2020, Mohammed VI University of Health Sciences researchers studied the application of c-reactive protein as an early identifying market for COVID infection diagnosis and its severity. According to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) information guide, c-reactive protein (CRP) can be considered as one of the potential markers that can be used to evaluate severity of SARS-CoV 2 infection prognostics and therapeutics monitoring.

Moreover, c-reactive protein testing and its results can be used alongside other clinical parameters to carry out evaluation as well as follow up of the COVID infection. In this backdrop, various companies such as Aidian and Abbott have introduced products that act as supportive tool for diagnosis of COVID 19 infection. For example, Aidian has introduced easy-to-use QuickRead Go c-reactive protein tests with a portable QuickRead Go tool for a quantitative analysis and measurement of CRP. Likewise, Abbott introduced Affinion 2 Analyzer CRP test which provide results in about 3 minutes. Thus, rising demand for CRP testing in clinical research for the diagnosis of COVID 19 infection severity is expected to boost the growth of the c-reactive protein testing market.

Application of CRP in Cardiovascular Diseases Opens Doors for C-Reactive Protein Testing Market

Application of c-reactive protein testing in the diagnosis of cardiovascular disorders is expected to rise at a significant pace worldwide. Increasing prevalence of cardiovascular disorders has triggered need for developing an effective and a faster diagnosis method. C-reactive proteins can act as an indicator for the identification of CVD (Cardiovascular Disorders) as it can act as a biological marker for detection of atherosclerosis that is essentially stacking of cholesterol inside the walls of the blood vessel which creates inflammation inside the vessel walls. That said, patients suffering from cardiovascular disorders typically have a higher level of C-reactive proteins (CRP). In addition, high sensitivity c-reactive protein level rises with several risk factors, for instance, smoking, obesity and aging. To conclude, if the individual is overweight or a habitual smoker, the CRP level in his body will rise indicating a possibility of developing cardiovascular disorders. In this backdrop, high incidence rate of CVD has encouraged researchers to focus on c-reactive protein testing in cardiovascular applications.

According to analysis carried out by World Heart Federation, coronary heart disorders are considered to be one of the major causes of mortality worldwide. Approximately 3.8 million and 3.4 million men and women die from coronary heart disorders each year respectively. Off these, 80% deaths take place in medium and low-income countries. Considering the above aspects, it becomes imperative to establish faster and efficient method for CVD diagnosis, which is expected to fuel the demand for c-reactive protein testing in cardiovascular diseases identification.

North America Likely to Cement Dominance in Global C-Reactive Protein Testing Market

Developed economies in North America are expected to showcase higher growth potential with respect to use of c-reactive protein testing. This can be primarily attributed towards adoption of advanced and innovative technology in the healthcare domain coupled with increasing importance of clinical research in the region. Rising prevalence of cancer in North America, especially in the United States, demand for c-reactive protein testing is likely to increase at a significant rate. Prostate cancer is one of the most diagnosed cancers in United States and leading cause of death, according to American Cancer Society.

As per Prostate Cancer Foundation, prostate cancer is considered as one of the most occurring non-skin cancer types in the US. In addition, according to CDC (Center for Disease Control and Prevention), about 18 million adults with age ranging 20 and above are expected to develop CAD (Coronary Artery Disease), wherein 2 in 10 mortalities will occur due to coronary heart disease among adults with age ranging from 65 and above. This has created a wide scope for introducing novel techniques to identify occurrence of such chronic ailments, which is expected to fuel the adoption of c-reactive protein testing, given the favorable government policies apropos to healthcare reimbursements and infrastructure. That said, North America is poised to cement its dominance in the c-reactive protein testing market in the coming years.

C-Reactive Protein Testing Market: Competitive Landscape

Few of the major players in the c-reactive protein testing market include 

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• bioMérieux
• Thermo Fisher Scientific
• Danaher Corporation (Beckman Coulter & Leica Biosystems)
• Becton, Dickinson and Company (BD)
• Bio-Rad Laboratories, Inc.
• Horiba, Ltd.
• Sysmex Corporation
• Olympus Corporation
• Hoffmann-La Roche Ltd. (CRP reagents & platforms)
• Tosoh Corporation
• Siemens Healthcare Diagnostics
• QuidelOrtho Corporation

Global C-Reactive Protein Testing Market is Segmented as Below:

By Application

• Diabetes
• Rheumatoid Arthritis
• Cardiovascular Disease
• Inflammatory Bowel Disease
• Others

By Assay Type

• Enzyme-linked immunosorbent assay (ELISA)
• Chemiluminescence Immunoassay (CLIA)
• Immunoturbidimetric assays
• Others

By End Use

• Clinics
• Hospitals
• Diagnostic Labs

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa